clinical trial · NCT07581951
A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH
Haisco Pharmaceutical Group Co., Ltd.·phase3·not yet recruiting·n = 400
MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH (Non-Alcoholic Steatohepatitis)HSK31679Placebo
brief summary
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of HSK31679 compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) .
started
Jun 30, 2026
primary completion
Jun 30, 2029
completion
Dec 30, 2032
last updated
Jun 17, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of HSK31679 in Patients With Metabolic Dysfunction Associated Steatohepatitis (MASH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol